Attorney-reviewed
Dupixent CTCL information reviewed by Keke Feng, Esq.
- Focused on CTCL and related T-cell lymphoma inquiries
- Clear review path for patients and families
Dupixent CTCL Litigation
Dupixent and T-Cell Lymphoma: What Patients Were Not Told
Lawsuits allege that Sanofi and Regeneron did not adequately warn patients and doctors about reported CTCL and T-cell lymphoma safety concerns involving Dupixent. No court has made a final determination on those allegations.
If you used Dupixent and were later diagnosed with cutaneous T-cell lymphoma (CTCL), mycosis fungoides, Sézary syndrome, or another related T-cell lymphoma, MedLaw Group can review basic information and help identify what facts may matter next.
Dupixent lawsuits are focused on allegations that patients and doctors were not adequately warned about reported CTCL-related risks. Published studies, adverse-event data, and court filings have raised questions about certain Dupixent treatment histories followed by CTCL-related diagnoses, including questions about timing, progression, and whether CTCL may have been difficult to recognize in some histories.
The site is focused on CTCL and related T-cell lymphoma diagnoses, rather than every cancer or every lymphoma diagnosis after Dupixent. Dupixent was also prescribed for asthma, COPD, nasal polyps, and other conditions — not only eczema. Patients treated for any approved Dupixent indication may submit an inquiry.
Attorney-Reviewed. Biopharma-Informed. Personally Accessible.
This Dupixent CTCL resource is reviewed with legal judgment and biopharma industry insight. MedLaw brings pharmaceutical industry knowledge, attorney perspective, federal complex litigation experience, and a focused personal approach to help patients and families understand what facts may matter in a Dupixent-related CTCL or T-cell lymphoma inquiry.
Keke Feng, Esq.
Attorney-reviewed Dupixent CTCL resource
Attorney-reviewed CTCL information
Focused information for Dupixent users with CTCL or related T-cell lymphoma diagnoses.
Source-reviewed litigation updates
Updates grounded in court, regulatory, labeling, and medical source materials.
Co-counsel review pathway
When appropriate, inquiries can be reviewed through a litigation-informed pathway.
What this site covers
Dupixent & CTCL
Medical background, diagnosis history, and records that may matter.
Read Dupixent & CTCLLitigation status
JPML filings, MDL developments, and failure-to-warn allegations.
Read Litigation UpdatesInitial case review
Basic facts that may help determine whether follow-up may be appropriate.
Review Key FactorsInformation that may help an initial review
Helpful starting information may include approximate Dupixent treatment dates, the CTCL-related diagnosis name, dermatology or oncology records, pathology reports, symptom timeline notes, and whether biopsy, specialist review, or second opinion was involved.
Frequently Asked Questions
Who is this site for?
This site is for people who used Dupixent and were later diagnosed with CTCL, mycosis fungoides, Sézary syndrome, or another related T-cell lymphoma, and who want to understand whether their medical history may warrant initial review.
What diagnoses are the focus of this site?
This site is focused on CTCL and related T-cell lymphoma diagnoses, including mycosis fungoides and Sézary syndrome. Other cancers or unrelated lymphoma diagnoses may involve different medical and legal questions.
Why are Dupixent and CTCL being discussed?
Court filings, medical literature, adverse-event data, and regulatory materials have raised questions about certain Dupixent treatment histories followed by CTCL-related diagnoses. The litigation remains developing, and individual histories still require case-specific review.
What information may matter for an initial review?
Helpful information may include Dupixent treatment dates, the diagnosis received, dermatology or oncology records, pathology reports, and a short timeline of symptoms, treatment, and diagnosis.
Does submitting a form create an attorney-client relationship?
No. Submitting information requests an initial review only and does not create an attorney-client relationship or mean a matter has been accepted.
Why MedLaw Group
MedLaw Group focuses on pharmaceutical and medical device injury matters, including emerging mass tort and MDL litigation. The attorney behind MedLaw Group brings experience with complex federal litigation and prior in-house pharmaceutical work, which helps the team understand how drug safety signals, labeling decisions, and risk communications may be evaluated.
Start Free Case Review
If you used Dupixent and were later diagnosed with CTCL or another related T-cell lymphoma, you may submit basic information for a focused initial review. Legal deadlines may vary by state, and diagnosis timing can matter.